КЛИНИКО-СТАТИСТИЧЕСКИЙ АНАЛИЗ ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ
https://doi.org/10.20514/2226-6704-2018-8-5-389-393
Аннотация
Об авторах
Н. Ф. ПлавуновРоссия
Москва.
Н. И. Гапонова
Россия
Москва.
В. А. Кадышев
Россия
Москва.
В. Р. Абдрахманов
Россия
Москва.
А. Е. Акимов
Россия
Москва.
А. И. Кулик
Россия
Москва.
Список литературы
1. Медико-демографические показатели Российской Федерации в 2014 году. Статистический справочник. М.: Минздрав России. 2014; 186 с.
2. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ. Российский кардиологический журнал. 2013; 4: 1-100.
3. P. Kirchhof, S.Benussi, Dipak Kotecha et al. 2016 ESC Guidelines forthe management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016.
4. Aksnes T.A., Kjeldsen S.A. A link between hypertension and atrial fibrillation: methods of treatment and prevention. Curr Vasc Pharmac. 2010; 6: 769-774.
5. Sun Y, Hu D. The link between diabetes and atrial fibrillation: cause or correlation? J. Cardiovascular Dis 2010; 10-11.
6. Heeringa J., van der Kuip D.A., Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Roterdam study. Eur Heart J. 2006; 27: 949-953.
7. Grond M., Jauss M., Hamann G., Stark E., Veltkamp R., Nabavi D., Horn M., Weimar C., Kohrmann M., Wachter R., Rosin L., Kirchhof P. Improved detection of silent atrial fibrillation using 72 hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke. 2013; 44: 3357-3364.
8. Nabauer M., Gerth A., Limbourg T et al. The Registry of the German Competence NET work on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009; 11: 423-434.
9. Hart R.G., Pearce L.A., Aguilar M.I. Metaanalysis: antithrombotic therapy to prevent stroke in patients who have non valvular atrial fibrillation. Ann Intern Med. 2007; 146: 857-867.
10. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Eng J Med. 2009; 361: 1139-1151.
11. ROCKET AF Study investigators6 rivaroxaban– once daily, oral, direct factor xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation6 rationale and design of the ROCKET AF study. Amer Heart J. 2010;159: 340-347.
12. Lopes R.D., Alexander J.H., Al-Khatib S.M., et al. Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial: design and rationale. Amer Heart J. 2010; 159: 331-339.
13. Chugh S.S., Blackshear J.L., Shen W.K. et al. Epidemiology and natural history of atrial fibrillation: clinical implications. J Amer Coll Card. 2001; 37: 371-378.
14. Kirchhof P., Auricchio A., Bax J., et al. Outcome parameters for trials in atrial fibrillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NET work (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J. 2007; 28: 2803–2817.
15. Colilla S., Grow A., Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Amer J Cardiol. 2013; 112: 1142-1147.
16. Mc Murrau J., Adamopoulos S., Anker S. ESC guidelines for the diagnosis and treatment of acute and chronic heart faiture 2012. Eur Heart J. 2012; 33: 1787- 1847.
Рецензия
Для цитирования:
Плавунов Н.Ф., Гапонова Н.И., Кадышев В.А., Абдрахманов В.Р., Акимов А.Е., Кулик А.И. КЛИНИКО-СТАТИСТИЧЕСКИЙ АНАЛИЗ ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ. Архивъ внутренней медицины. 2018;8(5):389-393. https://doi.org/10.20514/2226-6704-2018-8-5-389-393
For citation:
Plavunov N.F., Gaponova N.I., Kadyshev V.A., Abdrachmanov V.R., Akimov A.E., Kulik A.I. CLINICAL AND STATISTICAL EVALUATION OF THE CALLS OF PATIENTS WITH ATRIAL FIBRILLATION. The Russian Archives of Internal Medicine. 2018;8(5):389-393. https://doi.org/10.20514/2226-6704-2018-8-5-389-393